PLoS ONE (Jan 2012)

Porcine model of hemophilia A.

  • Yuji Kashiwakura,
  • Jun Mimuro,
  • Akira Onishi,
  • Masaki Iwamoto,
  • Seiji Madoiwa,
  • Daiichiro Fuchimoto,
  • Shunichi Suzuki,
  • Misae Suzuki,
  • Shoichiro Sembon,
  • Akira Ishiwata,
  • Atsushi Yasumoto,
  • Asuka Sakata,
  • Tsukasa Ohmori,
  • Michiko Hashimoto,
  • Satoko Yazaki,
  • Yoichi Sakata

DOI
https://doi.org/10.1371/journal.pone.0049450
Journal volume & issue
Vol. 7, no. 11
p. e49450

Abstract

Read online

Hemophilia A is a common X chromosome-linked genetic bleeding disorder caused by abnormalities in the coagulation factor VIII gene (F8). Hemophilia A patients suffer from a bleeding diathesis, such as life-threatening bleeding in the brain and harmful bleeding in joints and muscles. Because it could potentially be cured by gene therapy, subhuman animal models have been sought. Current mouse hemophilia A models generated by gene targeting of the F8 have difficulties to extrapolate human disease due to differences in the coagulation and immune systems between mice and humans. Here, we generated a porcine model of hemophilia A by nuclear transfer cloning from F8-targeted fibroblasts. The hemophilia A pigs showed a severe bleeding tendency upon birth, similar to human severe hemophiliacs, but in contrast to hemophilia A mice which rarely bleed under standard breed conditions. Infusion of human factor VIII was effective in stopping bleeding and reducing the bleeding frequency of a hemophilia A piglet but was blocked by the inhibitor against human factor VIII. These data suggest that the hemophilia A pig is a severe hemophilia A animal model for studying not only hemophilia A gene therapy but also the next generation recombinant coagulation factors, such as recombinant factor VIII variants with a slower clearance rate.